Replies to post #202498 on Biotech Values

[dewophile]

At first blush this sound analogous to how we make mutant / resistant strains in the lab

and pulsing antibiotics is a great way to induce resistance. point taken. Whether or not such a strategy will result in resistant leukemic cells is a theoretical risk

If you are actually lowering disease burden, why not let the CAR-Ts persist?

If you have an AE that is correlated to dx burden like cytokine storm then it could abate as the disease is eradicated without the need for turning off the T cells, but there still could be cases where a reprieve could be the safest course of action

Not trying to be combative or obtuse, just trying to reason out the setting where an On/Off CAR-T would be necessary

no offense taken - you make valid points about how an on/off is by no means a panacea and may have limited usefulness, especially once there is more experience w prophylaxis and management of the AEs. However I also think it is premature to be totally dismissive of the value of such switches

[DFRAI]

CAR on-off switch

1. To ensure that CAR is strong enough and persistent enough to generate anti-cancer response.
2. To be able to control Cytokine release storm
3. Control neurotoxicities

Able to fine tune the CAR and immune response = tolerable treatment, optimized etc

I am just a biotech green investor...